Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Cash from Operations (2016 - 2025)

Acro Biomedical (ACBM) has 10 years of Cash from Operations data on record, last reported at 25377.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 141.34% year-over-year to 25377.0; the TTM value through Dec 2025 reached 196302.0, down 435.0%, while the annual FY2025 figure was 196302.0, 435.0% down from the prior year.
  • Cash from Operations reached 25377.0 in Q4 2025 per ACBM's latest filing, up from 54410.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 432770.0 in Q2 2021 and bottomed at 345777.0 in Q2 2022.
  • Average Cash from Operations over 5 years is 4829.3, with a median of 11590.5 recorded in 2022.
  • Peak YoY movement for Cash from Operations: skyrocketed 3228.07% in 2022, then crashed 1411.59% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 60506.0 in 2021, then skyrocketed by 82.53% to 10568.0 in 2022, then dropped by 19.35% to 12613.0 in 2023, then grew by 16.63% to 10515.0 in 2024, then crashed by 141.34% to 25377.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 25377.0 in Q4 2025, 54410.0 in Q3 2025, and 93984.0 in Q2 2025.